drugset / Trial / NCT00444561

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

NCT00444561

Phase 2 Completed 184 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.

Timeline

Start
2004-08
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pramlintide Peptide Subcutaneous

Indications